tirzepatide vs semaglutide effectiveness weight loss and liraglutide for in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States Newer Weight-Loss Drugs Not Cost-effective

Gradual weight loss is often more sustainable

Patients randomized to tirzepatide achieved further weight loss, and those receiving placebo gained weight during the period of 72 weeks, following the intensive lifestyle intervention (efficacy estimand: 21.1% vs

Despite the difference in milligram amounts, each drug is calibrated to its own potency scale

After discontinuation, close monitoring is essential: weight should be checked every 4-8 weeks initially, and for diabetes patients, self-monitoring of blood glucose or continuous glucose monitoring should continue as indicated, with A1C assessment within approximately 3 months of stopping to detect metabolic deterioration early and implement alternative management strategies